Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


27.08.2018

3 BJU Int
1 Br J Cancer
1 Cancer Res
1 Clin Cancer Res
2 Eur Radiol
4 Eur Urol
1 Int J Oncol
1 Int J Urol
1 J Clin Oncol
2 J Urol
2 JAMA
1 Mod Pathol
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A
4 Prostate
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int


  1. NICE Advice - Prolaris gene expression assay for assessing long-term risk of prostate cancer progression: (c) NICE (2016) Prolaris gene expression assay for assessing long-term risk of prostate cancer progression.
    BJU Int. 2018;122:173-180.
    PubMed     Text format    

  2. CULIG Z
    The way towards understanding possible multiple functions of AR V7 in prostate cancer.
    BJU Int. 2018;122:169.
    PubMed     Text format    

  3. THOMPSON JE, Stricker PD
    MRI improves active surveillance of prostate cancer however biopsy is still crucial.
    BJU Int. 2018;122:E1-E2.
    PubMed     Text format    


    Br J Cancer

  4. ROMERO-LAORDEN N, Lozano R, Jayaram A, Lopez-Campos F, et al
    Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study).
    Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0123.
    PubMed     Text format     Abstract available


    Cancer Res

  5. XIAO L, Tien JC, Vo J, Tan M, et al
    Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-0941.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  6. GRUBMULLER B, Baltzer PA, Hartenbach S, D'Andrea D, et al
    PSMA ligand PET/MRI for primary prostate cancer: Staging performance and clinical impact.
    Clin Cancer Res. 2018 Aug 23. pii: 1078-0432.CCR-18-0768.
    PubMed     Text format     Abstract available


    Eur Radiol

  7. PIERRE T, Cornud F, Colleter L, Beuvon F, et al
    Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone?
    Eur Radiol. 2018;28:2236-2245.
    PubMed     Text format     Abstract available

  8. DYRBERG E, Hendel HW, Huynh THV, Klausen TW, et al
    (68)Ga-PSMA-PET/CT in comparison with (18)F-fluoride-PET/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study.
    Eur Radiol. 2018 Aug 21. pii: 10.1007/s00330-018-5682.
    PubMed     Text format     Abstract available


    Eur Urol

  9. FORSMARK A, Gehrman J, Angenete E, Bjartell A, et al
    Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial.
    Eur Urol. 2018 Aug 21. pii: S0302-2838(18)30560.
    PubMed     Text format     Abstract available

  10. CULIG Z
    Innovative Therapies to Overcome Resistance to Enzalutamide: Perspective on the Use of Darolutamide.
    Eur Urol. 2018;73:9-10.
    PubMed     Text format    

  11. LEE B, Kim JH
    Re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e13-e14.
    PubMed     Text format    

  12. UREN AD, Cotterill N, Harding C, Hillary C, et al
    Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.
    Eur Urol. 2018;73:e15-e16.
    PubMed     Text format    


    Int J Oncol

  13. HAN G, Zhang X, Liu P, Yu Q, et al
    Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer.
    Int J Oncol. 2018 Aug 16. doi: 10.3892/ijo.2018.4526.
    PubMed     Text format     Abstract available


    Int J Urol

  14. FUJITA K, Nonomura N
    Urinary biomarkers of prostate cancer.
    Int J Urol. 2018 Aug 21. doi: 10.1111/iju.13734.
    PubMed     Text format     Abstract available


    J Clin Oncol

  15. CATTON CN, Lukka H, Martin J
    Prostate Cancer Radiotherapy: An Evolving Paradigm.
    J Clin Oncol. 2018 Aug 23:JCO2018793257. doi: 10.1200/JCO.2018.79.3257.
    PubMed     Text format     Abstract available


    J Urol

  16. LOUGHLIN KR
    Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is not Informative.
    J Urol. 2018 Aug 18. pii: S0022-5347(18)43724-X. doi: 10.1016/j.juro.2018.
    PubMed     Text format    

  17. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.
    J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.
    PubMed     Text format     Abstract available


    JAMA

  18. MARTIN RM
    Power of a Trial Investigating a Low-Intensity PSA-Based Screening Intervention-Reply.
    JAMA. 2018;320:600-601.
    PubMed     Text format    

  19. PINSKY PF
    Power of a Trial Investigating a Low-Intensity PSA-Based Screening Intervention.
    JAMA. 2018;320:600.
    PubMed     Text format    


    Mod Pathol

  20. BRAMHECHA YM, Rouzbeh S, Guerard KP, Scarlata E, et al
    The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.
    Mod Pathol. 2018 Aug 23. pii: 10.1038/s41379-018-0107.
    PubMed     Text format     Abstract available


    Oncol Rep

  21. WANG J, Yang X, Li R, Wang L, et al
    Long non-coding RNA MYU promotes prostate cancer proliferation by mediating the miR-184/c-Myc axis.
    Oncol Rep. 2018 Aug 20. doi: 10.3892/or.2018.6661.
    PubMed     Text format     Abstract available


    PLoS One

  22. YE Y, Li SL, Wang SY
    Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    PLoS One. 2018;13:e0198055.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  23. DUDANI JS, Ibrahim M, Kirkpatrick J, Warren AD, et al
    Classification of prostate cancer using a protease activity nanosensor library.
    Proc Natl Acad Sci U S A. 2018 Aug 20. pii: 1805337115.
    PubMed     Text format     Abstract available


    Prostate

  24. DUGUE PA, Dowty JG, Joo JE, Wong EM, et al
    Heritable methylation marks associated with breast and prostate cancer risk.
    Prostate. 2018;78:962-969.
    PubMed     Text format     Abstract available

  25. VAN DUIJN PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, et al
    Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.
    Prostate. 2018;78:1013-1023.
    PubMed     Text format     Abstract available

  26. TOMMASI S, Pilato B, Carella C, Lasorella A, et al
    Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23710.
    PubMed     Text format     Abstract available

  27. XIE W, Stopsack KH, Drouin SJ, Fu H, et al
    Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival.
    Prostate. 2018 Aug 23. doi: 10.1002/pros.23712.
    PubMed     Text format     Abstract available


    Urology

  28. CAPOGROSSO P, Capitanio U, Vertosick EA, Ventimiglia E, et al
    Temporal trend in incidental prostate cancer detection at surgery for benign prostatic hyperplasia.
    Urology. 2018 Aug 20. pii: S0090-4295(18)30783.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: